Nektar TherapeuticsNKTRNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank64
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

Latest
-6.53
↑ 76% vs avg
Percentile
P64
Within normal range
Streak
2 yr
Consecutive declineContracting
Average
-27.16
Historical baseline
PeriodValueYoY Change
2025-6.53-126.8%
2024-2.88-268.5%
2023-0.78+45.7%
2022-1.44+74.4%
2021-5.62+25.8%
2020-7.58+29.1%
2019-10.69-231.4%
20188.13+103.6%
2017-224.68-1049.4%
2016-19.55-